Skip to main content
Premium Trial:

Request an Annual Quote

HGS Completes Phase I Study of Its Second Genome-Based Drug


ROCKVILLE, Md.--Human Genome Sciences announced last week that it successfully completed phase I clinical studies of its second genomics-derived drug. Keratinocyte growth factor-2 (KGF-2) is a therapeutic protein being evaluated as a treatment for wound-healing. Successful phase I studies of Myeloid progenitor inhibitory factor-1 were announced last month. The drugs are the first two therapeutic products discovered using genomic techniques to enter clinical trials, the company claimed. CEO William Haseltine said HGS could now be called "a pioneer in genomic drug development as well as in genomics."

Filed under

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.